Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10919480 | Radiotherapy and Oncology | 2013 | 6 Pages |
Abstract
PB-APBI consisting of 30 CGE in six CGE fractions once daily for five consecutive days can be delivered with excellent disease control and tolerable skin toxicity to properly selected patients with early-stage breast cancer. Multiple-field PB-APBI may achieve a high rate of good-to-excellent cosmetic outcomes. Additional clinical trials with larger patient groups are needed.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ji Hyun Chang, Nam Kwon Lee, Ja Young Kim, Yeon-Joo Kim, Sung Ho Moon, Tae Hyun Kim, Joo-Young Kim, Dae Yong Kim, Kwan Ho Cho, Kyung Hwan Shin,